Azerbaijan Sterile Device Registration: Validation, Bioburden, Pyrogenicity and Sterility Documents

1. Key takeaways

Sterile devices require, in addition to the 11 dossier items, a dedicated package under Article 4.2.7: a document issued by the manufacturer containing the test methods and packaging validation information, microbiological content (bioburden level) test results, pyrogenicity test results, sterility test results and process validation information, submitted with a notarised translation into Azerbaijani.

This package is the only technical document among the 11 items that requires a notarised translation (the other being the registration-type documents under Article 4.2.2), and it is also the item with the highest technical barrier. The four result categories — bioburden, pyrogenicity, sterility and the two validation tracks — must each be documented separately, not merged into a single summary certificate.

Because the examination regime of Resolution No. 502 allows AEC to perform testing, deficiencies in this package can cascade into follow-up questions during the expertise stage, extending the timeline well beyond the nominal 7 working days for issuance.

2. Legal basis

• Resolution No. 345 of the Cabinet of Ministers of the Republic of Azerbaijan dated 18 July 2024 on the Rules for State Registration of Medicines, Drug Substances and Medical Devices, Their Entry into the State Register and Maintenance of the State Register (effective 19 July 2024; Xalq qəzeti No. 151 of 20 July 2024; Legislative Bulletin 2024 No. 7, item 906; repealing Resolution No. 108 of 13 July 2007 as of 20 July 2024): Article 4.2.7 (additional documents for sterile devices with notarised Azerbaijani translation), Article 4.2.6 (biosafety information), Article 4.3 (Article 4.2.6 not applicable to devices not contacting the human body), Article 5.1.4 (refusal for document inconsistencies), Article 10.4.4 (primary and secondary packaging descriptions recorded in the register).
• Decision No. 8 of the Collegium of the Ministry of Health of the Republic of Azerbaijan dated 21 May 2024 on the Classification of Medical Devices by Risk Degree (adopted under the second sentence of Article 6.8 of the Law on Medicines; signed by Minister Teymur Musayev; submitted to the Ministry of Justice within 3 days): Article 3.1.4 (sterility as one of the 8 determination dimensions), Article 2.1.2 (definition of risk degree).
• Resolution No. 502 of the Cabinet of Ministers of the Republic of Azerbaijan dated 25 December 2019 on the Rules for Performing Expertise of Medicines (including simplified expertise) (Xalq qəzeti No. 290 of 28 December 2019; Legislative Bulletin 2019 No. 12, item 2083; effective 1 July 2020) — the expertise implementation rules under which AEC may perform testing.

3. Expert insights

Insight one: sterility is itself a classification dimension and simultaneously a dossier-loading condition. Article 3.1.4 of Decision No. 8 lists whether the device is supplied sterile as one of the 8 determination dimensions. The same device supplied sterile and non-sterile can end up at different risk degrees, changing the registration pathway and dossier depth. Fix the supply state at the product-selection stage; switching to sterile mid-way triggers modification of the state registration under Article 1.5.

Insight two: Article 4.2.7 demands a validation-plus-testing two-track package, not a single sterility test report. The provision expressly lists: validation information for test methods and packaging, microbiological content (bioburden level) results, pyrogenicity results, sterility results, and process validation information. A final-product sterility report alone does not satisfy the article.

Insight three: the technical density of the translation drives rework risk for this item. Bioburden, pyrogenicity, sterility and process validation are terminology-heavy. A mistranslation can be treated under Article 5.1.4 as an inconsistency related to quality, effectiveness or safety — which is a ground for refusal, not a deficiency notice. Use translators with device backgrounds, have the manufacturer’s technical department review terminology, and only then send the text to notarisation.

Insight four: Articles 4.2.6 and 4.2.7 are two independent document lines. Article 4.2.6 is biosafety information (exempt for devices not contacting the body, under Article 4.3), while Article 4.2.7 is the sterile-specific package (with no product-category exemption — its only applicability condition is sterile supply). Both can apply simultaneously; do not omit 4.2.7 because 4.2.6 was submitted.

4. Practical recommendations

1. Fix the supply state (sterile or non-sterile) at the selection stage; any later change follows modification of the state registration under Article 1.5.
2. Prepare the validation-plus-testing package under 4.2.7: packaging and method validation, bioburden, pyrogenicity, sterility and process validation — five components, none optional.
3. Have translations prepared by translators with device backgrounds, reviewed by the manufacturer’s technical department before domestic notarisation in Azerbaijan.
4. Keep the 4.2.6 biosafety materials as a separate volume and annotate each with its article number in the submission list.
5. Retain the methodological basis and versions of test reports to support follow-up explanation during AEC expertise under Resolution No. 502.
6. Record in the classification rationale how the sterility dimension influenced the degree, to ease future modification assessments.

5. Verification checklist

• □ The supply state (sterile / non-sterile) is fixed and recorded in the classification rationale.
• □ All five components of Article 4.2.7 are prepared (packaging and method validation, bioburden, pyrogenicity, sterility, process validation).
• □ The notarised Azerbaijani translation is complete and terminology-reviewed by the technical department.
• □ The package is bound separately from the Article 4.2.6 materials and annotated with its article number.
• □ Test methodology references and report versions are retained for follow-up.
• □ The influence of the sterility dimension is documented in the classification rationale.

• Article 13 — The 11 dossier items one by one: 4.2.1 to 4.2.11: https://www.grzanglobal.com/azerbaijan-medical-device-registration/dossier-11-items-breakdown/
• Article 16 — Devices incorporating a medicinal substance: the expertise-first additional pathway: https://www.grzanglobal.com/azerbaijan-medical-device-registration/devices-containing-medicinal-substance/
• Article 26 — Biosafety information: when it can be omitted: https://www.grzanglobal.com/azerbaijan-medical-device-registration/biosafety-information-exemptions/

Regulatory information verified as of October 30, 2026.

GRZAN supports manufacturers and authorised representatives in preparing the Article 4.2.7 sterile-device package for medical devices in Azerbaijan, from validation and bioburden documentation to notarised Azerbaijani translations reviewed for technical accuracy. For tailored assistance with your Azerbaijan sterile device documentation, contact us at info@grzanglobal.com.